Sun Pharma to receive FDA Form 483 on Halol unit: Report

26 Sep 2014 Evaluate

Team of US FDA (Food and Drug Administration) inspectors, which recently conducted a surprise audit on a Gujarat unit of Sun Pharmaceutical Industries, has reportedly submitted Form 483. Submission of Form 483 means the FDA team found certain procedural issues with respect to the plant's running and seeks corrective action but may not imply an immediate import ban.

The FDA team has made 23 observations (four for injectable units, four for oral solid unit and rest for the quality-control lab) at the Halol unit in Gujarat, which accounts for about 25 percent of Sun’s US sales. The US market accounts for 60 percent of the company’s total sales. Though, the FDA did not find any data integrity issues with the plant.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1735.85 -25.60 (-1.45%)
09-Jan-2026 13:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.85
Dr. Reddys Lab 1215.00
Cipla 1464.00
Zydus Lifesciences 894.85
Lupin 2174.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×